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Abstract
Background: Ticagrelor is a reversibly binding, direct-acting, oral, P2Y12 antagonist used for the prevention of
atherothrombotic events in patients with coronary artery disease (CAD). Ticagrelor blocks adenosine reuptake through
the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating
adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Meanwhile, adenosine
plays an important role in triggering ischemic preconditioning through the activation of the A1 receptor. Therefore, an
increase in ticagrelor-enhanced adenosine bioavailability may confer beneficial effects through mechanisms related to
preconditioning activation and improvement of coronary microvascular dysfunction.
Methods: To determine whether ticagrelor can trigger ischemic preconditioning and influence microvascular function,
we designed this prospective, open-label, pilot study that enrolled patients with stable multivessel CAD requiring staged,
fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI). Participants will be randomized in 1:1 ratios
either to ticagrelor (loading dose (LD) 180mg, maintenance dose (MD) 90mg bid) or to clopidogrel (LD 600mg, MD 75
mg) from 3 to 1 days before the scheduled PCI. The PCI operators will be blinded to the randomization arm. The primary
endpoint is the delta (difference) between ST segment elevations (in millimeters, mm) as assessed by intracoronary
electrocardiogram (ECG) during the two-step sequential coronary balloon inflation in the culprit vessel. Secondary
endpoints are 1) changes in coronary flow reserve (CFR), index of microvascular resistance (IMR), and FFR measured in the
culprit vessel and reference vessel at the end of PCI, and 2) angina score during inflations. This study started in 2018 with
the aim of enrolling 100 patients. Based on the rate of negative FFR up to 30% and a drop-out rate up to 10%, we expect
to detect an absolute difference of 4mm among the study arms in the mean change of ST elevation following repeated
balloon inflations. All study procedures were reviewed and approved by the Ethical Committee of the Catholic University
of Sacred Heart.
Discussion: Ticagrelor might improve ischemia tolerance and microvascular function compared to clopidogrel, and these
effects might translate to better long-term clinical outcomes.
Trial registration: EudraCT No. 2016–004746-28. No. NCT02701140.
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Background
Rationale
Ticagrelor is a reversibly binding, direct-acting, oral P2Y12
antagonist used for the prevention of atherothrombotic
events in patients with acute coronary syndrome (ACS) [1].
It does not belong to thienopyridines; it is a carbocyclic nu-
cleoside, representing a “first-in-class” cyclopentyl-triazolo-
pyrimidine. In two phase II studies, dyspnea was noted to
occur as a side effect to ticagrelor in a dose-dependent fash-
ion, and in the PLATO study, a 6% absolute excess of dys-
pnea was observed in ticagrelor-treated patients compared
with patients treated with clopidogrel [1]. In the ONSET/
OFFSET study, dyspnea was more commonly associated
with ticagrelor therapy in comparison with clopidogrel and
placebo in patients with stable coronary artery disease
(38.6%, 9.3%, and 8.3%, respectively) but was not associated
with any adverse change in cardiac or pulmonary function
[2]. Similar results were later confirmed in the population
of patients with ACS [3].
The mechanisms for this side effect are largely un-
known, although early data indicate that ticagrelor
blocks adenosine reuptake through inhibition of ENT-1
transporter by erythrocytes [4], and intravenous adeno-
sine infusion can cause transient dyspnea in the absence
of bronchoconstriction [5]. Another mechanism poten-
tially increasing adenosine levels by ticagrelor is reflected
in adenosine triphosphate (ATP) release from erythro-
cytes [6]. Moreover, the biochemical comparison be-
tween ticagrelor and adenosine suggests their molecular
similarity. Adenosine is a well-known key endogenous
molecule that regulates tissue functions by activating
four G-protein–coupled adenosine receptors: A1, A2A,
A2B, and A3. Adenosine accumulates in the extracellular
space in response to metabolic stress and cell damage,
and elevations of adenosine are commonly encountered
in conditions such as ischemia, hypoxia, inflammation,
and trauma. Adenosine confers protective effects on the
cell due to its anti-inflammatory, cardioprotective, cere-
broprotective, antisclerotic, and antifibrotic properties,
as well as by platelet inhibition and vasodilation [7].
Because to these effects of ticagrelor on adenosine
biochemistry, chronic adenosine overload induced by
ticagrelor was hypothesized to possibly contribute to
the vascular outcome benefit observed in the PLATO
trial, in addition to the inhibitory effect it has shown on
platelet activity via P2Y12 receptor inhibition. Very
recently, ticagrelor has been shown to increase
adenosine-induced physiological responses in healthy
human subjects by shifting the dose-response curve for
adenosine-induced coronary blood flow velocity (CBFV)
to the left and increasing area under the curve of CBFV
[8]. Moreover, among patients with non–ST-segment
elevation ACS that were treated with percutaneous cor-
onary intervention (PCI) and received a maintenance
dose of ticagrelor, a greater CBFV was observed com-
pared to patients that received prasugrel maintenance
dose in response to increasing adenosine concentra-
tions [9]. These effects seem consistent with pharmaco-
logically observed blockade of adenosine reuptake, as
one of the pleiotropic effects exerted by the ticagrelor.
An increase in adenosine bioavailability, as potentiated
by ticagrelor, could have beneficial effects by both in-
creasing coronary perfusion and enhancing the function
of the microcirculation.
Activation of preconditioning
Ischemic preconditioning, consisting in episodes of ische-
mia as short as 5min, followed by reperfusion, has been
showed to protect the heart from a subsequent longer cor-
onary artery occlusion by markedly reducing the amount of
necrosis. Adenosine plays a key role in triggering ischemic
preconditioning. Indeed, the stimulation of A1 adenosine
receptors triggers a complex pathway that includes the
epsilon isoform of protein kinase C, the ATP-dependent
potassium channels, and the mitochondrial permeability
transition pores, as well as other cellular pathways, like a
paradoxical protective release of oxygen radicals eventually
making cardiomyocytes more resistant to ischemia [10, 11].
In humans, examples of preconditioning are the pre-
infarction angina and the angina “warm-up” phenomenon.
Preconditioning can be reproduced experimentally by re-
petitive and sequential balloon inflations in the culprit cor-
onary artery during the PCI, subsequently producing less
chest pain and decrease in ST-segment elevation [12, 13].
Pharmacological preconditioning can be induced by
intravenous or intracoronary administration of adenosine
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or A1 agonists of adenosine [14]. In a recent study
performed in rabbits, investigators observed cardio-
protective effects of clopidogrel and cangrelor (the
intravenous analogue of ticagrelor) that were not
attributed to the platelet inhibition but rather to
activation of the signal transduction pathways of
pre- and postconditioning, involving the reperfusion
injury salvage kinases (RISK), including Akt and
extracellular-regulated kinase (ERK), as well as ad-
enosine A2B receptors, mitochondrial KATP chan-
nels, and redox signaling [15]. This cardioprotective
effect of cangrelor was confirmed in a primate ani-
mal model as well [16, 17].
Improvement of coronary microvascular dysfunction
Coronary microvascular dysfunction has been demon-
strated to affect the prognosis of ACS patients. Of
note, Furber et al. described that doppler flow velocity
parameters in the infarct-related artery are of prog-
nostic value for long-term cardiac events [18]. Add-
itionally, Takahashi et al. found an impaired coronary
flow reserve velocity (CFVR) in the infarct-related ar-
tery to be significantly associated with increased car-
diac event rates at long-term follow-up [19].
Furthermore, a microvascular function has been dem-
onstrated to be altered even in nonischemic regions
at distance from the infarcted myocardial tissue [20],
and van de Hoef et al. have recently shown that
microvascular dysfunction determined in the reference
vessel after PCI is associated with a significantly in-
creased long-term cardiac mortality [21].
Microvascular dysfunction is likely to occur also in
the setting of non-ST-elevation ACS. In a cohort of
83 non-ST-elevation myocardial infarction (NSTEMI)
patients, microvascular obstruction, as assessed by an
elevated index of microcirculatory resistance (IMR)
that is correlated with microvascular obstruction, was
detected by the magnetic resonance imaging and was
an independent predictor of adverse cardiovascular
outcomes [22]. Marzilli et al. found that in patients
with unstable angina, episodes of transient myocardial
ischemia at rest are associated with a brisk increase
in coronary microvascular resistance and that this in-
crease is prevented by the administration of antiplate-
let drugs [23]. Equally important, microvascular
dysfunction may also occur following successful PCI;
that is, coronary flow reserve has been shown to be
impaired in the vascular bed subtended by the treated
artery and requires up to 3 months for this micro-
vascular dysfunction to resolve [24]. Finally, coronary
microvascular reactivity to adenosine predicted ad-
verse outcomes in women evaluated for suspected is-
chemia as demonstrated in WISE study [25].
Pharmacology
Mechanism of action (taken from the SmPC of the drug in
study)
Ticagrelor, a member of the chemical class cyclopentyl
triazolo pyrimidines (CPTP), is an oral, direct-acting, se-
lective, and reversibly binding P2Y12 receptor antagonist
that prevents adenosine diphosphate (ADP)-mediated
P2Y12 dependent platelet activation and aggregation [26].
Ticagrelor does not prevent ADP binding but when bound
to the P2Y12 receptor prevents ADP-induced signal trans-
duction. Since platelets participate in the initiation and/or
evolution of thrombotic complications of the atheroscler-
otic disease, inhibition of platelet function has been shown
to reduce the risk of cardiovascular (CV) events such as
death, myocardial infarction, or stroke [27].
Ticagrelor also increases local endogenous adenosine
levels by inhibiting the equilibrated nucleoside transporter-
1 (ENT-1). Ticagrelor has been documented to augment
the following adenosine-induced effects in healthy subjects
and in patients with ACS: vasodilation (measured by coron-
ary blood flow increases in healthy volunteers and ACS
patients), inhibition of platelet function (in human whole
blood in vitro), and dyspnea [28, 29]. However, a link
between the observed increases in adenosine and clinical
outcomes (e.g., morbidity-mortality) has not been clearly
elucidated [11, 30].
Objectives
The main goal of this study is to assess the pleiotropic ef-
fects of ticagrelor that could represent possible mechanisms
for its beneficial effects on cardiovascular mortality and ad-
verse outcomes.
Primary objective
Ticagrelor may trigger ischemic preconditioning as com-
pared to clopidogrel in patients with stable multivessel
CAD that are undergoing staged PCI.
Secondary objectives
Ticagrelor may improve microvascular perfusion in the
myocardium of patients with stable multivessel CAD
that are undergoing staged PCI.
Study endpoints
Primary endpoint
The primary endpoint is the comparison of ticagrelor
and clopidogrel for the delta (difference in mm) of the
ST-segment elevation, as assessed by the intracoronary
ECG during two-step sequential coronary balloon infla-
tion in the index vessel.
Secondary endpoints
Secondary endpoints include the following:
D’Amario et al. Trials          (2020) 21:192 Page 3 of 13
1) Comparison of ticagrelor and clopidogrel on CFR,
IMR, and FFR measured in the index vessel at the
end of the PCI
2) Comparison of ticagrelor and clopidogrel on angina
score during coronary balloon inflation
Materials/Methods
TAPER-S trial design
This study is a prospective, randomized, blinded, end-
point trial that will enroll patients with multivessel CAD
requiring scheduled treatment of a second lesion located
in a nonculprit vessel. The typical patient will be a pa-
tient with purely stable CAD and a scheduled, FFR-
guided PCI of any vessel. Patient presenting initially with
an ACS, with an intermediate coronary lesion (40–80%
in severity, where functional evaluation of the stenosis
with FFR must be used based on clinical situation) in a
nonculprit coronary artery, for whom a delayed, FFR-
guided strategy is chosen, may also be included in the
study. In these patients, recovery of the microvascular
function requires that at least 1 month has elapsed be-
fore re-evaluation of the culprit lesion, as FFR in the
acute phase is known to be unreliable [31]. Screening/
randomization will take place 1 to 3 days before the
index procedure. Randomization will be blocked within
each study site, which will allow an even balance of pa-
tients to be randomized to either drug at each recruiting
center. Patients with FFR > 0.80 (no functionally signifi-
cant stenosis) will be excluded from the study (Figs. 1
and 2). The study will be conducted in Italy, involving A.
Gemelli Polyclinic of the Catholic University of the Sa-
cred Heart in Rome and Grosseto Hospital (Ospedale
della Misericordia Grosetto) in Grosetto, Italy.
The study is designed to have a total duration of 23
months, with an enrollment period of approximately 20
months. Each patient will be treated with the study drug
only during the in-hospital phase, for a minimum of 3
days (Day -1 to Day 1) up to a maximum of 7 days
(Day -1 to Day 5). The patient will be hospitalized (as
per usual clinical practice) from Day -3 to Day -1 (admis-
sion) to Day 0–5 of the study. The total number of en-
rolled patients will be one hundred (N = 100), with a
projected 10% drop-out rate and 30% of negative FFR as-
sessment (FFR > 0.80), with a final pool comprising 60
patients who will be evaluated in terms of primary and
secondary endpoints. Therefore, the study enrollment
will be stopped once one hundred patients are enrolled
(Fig. 3).
Fig. 1 Flow-chart for patients presenting with ACS
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Sample size
This is an exploratory and pilot study, aimed at evaluat-
ing the off-target effects of ticagrelor on ischemic pre-
conditioning. A sample size of 40–60 patients is, in
general, considered appropriate for a pilot study and
should provide important insights for the planning of a
future larger study and for estimating confidence inter-
vals [32]. Per our design, by assuming an absolute dif-
ference (delta) of 4 mm in the change of ST-segment
shift from the first to the second balloon inflation be-
tween the two compared groups, a magnitude similar
(albeit reversed) to the effect observed by Niccoli et al.
in a study demonstrating the negative preconditioning
effect of ethanol [33], we can infer that 30 patients per
group will be required to provide an 80% power to de-
tect a statistically significant difference between groups
at a significance level set at p < 0.05. The standard devi-
ation (SD) of the primary endpoint is expected to be
approximately 5 to 4 mm in each treatment group. By
enrolling one hundred patients, we also take into ac-
count those patients that will not require PCI after FFR
evaluation (as observed in the FAME II trial) [34].
The main statistical analysis to be undertaken is a
comparison of the primary endpoint (continuous
variables) between the two groups of 30 patients each
is a 2 × 2 analysis of variance (ANOVA) stratified by
treatment group. The co-primary safety endpoint,
which is a frequency value, will be analyzed using a
Fisher’s exact test.
Study population
Patients will be required to have a clinical indication to
undergo scheduled FFR-guided PCI. Two types of pa-
tients will be included:
1) Patients presenting initially with an ACS, with an
intermediate coronary lesion (40–80% in severity,
where functional evaluation with FFR must be used
based on clinical situation) in a nonculprit artery,
thus requiring a staged FFR-guided PCI (at least 1
month after the index ACS event)
2) Patients with a stable CAD and who are undergoing
scheduled FFR-guided PCI of any vessel
Patient selection
Inclusion criteria
The inclusion criteria are as follows:
Fig. 2 Flow-chart for patients presenting with stable coronary artery disease
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Fig. 3 Taper-S study flow-chart
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1) Signed and dated written Informed Consent
obtained prior to the inclusion in the trial
2) Age ≥ 18 and ≤ 75 years
3) Weight ≥ 60 kg
4) Patients must have a clinical indication to
undergo scheduled FFR-guided PCI (the two
types of patients to be included are noted in 5
and 6)
5) Patients presenting initially with an ACS, with an
intermediate coronary lesion (40–80% in severity,
where functional evaluation with FFR must be used
based on clinical situation) in a nonculprit artery,
thus requiring a staged FFR-guided PCI (at least 1
month after the index ACS event);
6) Patients with a stable CAD undergoing scheduled
FFR-guided PCI of any vessel
7) Patients already may be on the antiplatelet-directed
treatment with either ticagrelor (previous ACS
patients) or clopidogrel (stable patients)
Exclusion criteria
The exclusion criteria are as follows:
1) Known hypersensitivity to aspirin, clopidogrel,
ticagrelor, or any similar drug
2) Concomitant oral anticoagulant therapy, or need
for it (e.g., atrial fibrillation, mechanical valve,
etc.)
3) Need for a concomitant cardiac noncoronary
procedure, such as valve repair or replacement
4) Any previous history of ischemic stroke, intracranial
hemorrhage or disease (neoplasm, arteriovenous
malformation, or aneurysm)
5) Any active pathological bleeding or history of
significant gastrointestinal bleeding, genitourinary
bleeding or other site abnormal bleeding within the
previous 3months, other bleeding diathesis, or
considered by the Investigator to be at high risk for
bleeding
6) Concomitant oral or intravenous (IV) therapy with
strong CYP3A inhibitors, CYP3A substrates with
narrow therapeutic indices, or strong CYP3A
inducers. Any of such concomitant treatment will
be mapped and evaluated by the Investigator to
comply with the exclusion criteria
7) Increased risk of bradycardia events
8) Known pregnancy and/or breast-feeding
9) Severe uncontrolled chronic obstructive
pulmonary disease
10) Concomitant theophylline/aminophylline use
11) Baseline ECG with significant conduction
abnormalities (i.e., left ventricular hypertrophy with
repolarization abnormalities, left bundle branch
block, etc.)
12) Evidence of prior myocardial infarction by cardiac
imaging in the territory of the index vessel
13) Reduced left ventricular systolic function at
screening/randomization (left ventricular ejection
fraction < 40% within 48 h before index PCI, as
assessed by transthoracic echocardiography)
14) Clinical and laboratory signs of congestive heart failure
15) Presence of coronary collaterals on diagnostic
coronary angiography
16) Diffuse obstructive disease (≥ 70% stenosis) in the
distal segment of the target vessel
17) Left main and/or three-vessel CAD
18) End-stage renal disease (as assessed by the estimated
glomerular filtration rate CKD-EPI formula, eGFR
< 15 mL/min./1.73 m2)
19) Documented severe hepatic impairment (e.g.,
elevated liver enzymes, cirrhosis, etc.)
Study drugs
Dosing, posology, and route of administration
Ticagrelor will be given in a loading dose of 180 mg (on
Day -3 to -1), followed by a dose of 90 mg twice daily
(from Day 0 to discharge between Days 1 to Day 5, dur-
ing the index hospitalization). If the patient is chronic-
ally on ticagrelor, the loading dose will be omitted. In
case of missed dose, the lapses in therapy should also be
avoided. A patient who misses a dose of ticagrelor
should take only one tablet (their next dose) at its sched-
uled time.
Clopidogrel will be given in a loading dose of 600
mg (on Days -3 to -1), followed by a dose of 75 mg
once a day (from Day 0 to discharge during Days 1
to Day 5, during the index hospitalization). If the pa-
tient is chronically on clopidogrel, the loading dose
will be omitted. The antiplatelet switch will be man-
aged according to generally agreed consensus. The
details of the Antiplatelet Drug “switch” are specified
in the section below.
Antiplatelet drug switch
Patients could be randomized while on treatment to either
ticagrelor (previous ACS patients) or clopidogrel (stable pa-
tients). For those on long-term ticagrelor or clopidogrel
treatment randomized to the corresponding drug, no load-
ing dose will be given, and the patient will be continued on
the respective drug. For those randomized to the noncorre-
sponding group, the most recent recommendations regard-
ing antiplatelet drug “switch” will be followed [35, 36] - a
loading dose of the other drug will be given, 12–24 h before
the scheduled PCI procedure. For patients previously on a
long-term ticagrelor treatment, a 24-h washout period (i.e.,
the withdrawing of a single dose) will be applied before clo-
pidogrel loading dose is initiated, to aid in clearance of the
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reversible platelet inhibition by ticagrelor and its main me-
tabolite [36]. For both ticagrelor and clopidogrel, the last
drug dose will be given at least 4 ± 1 h before the start of
the index procedure [37]. After the index procedure, long-
term antiplatelet treatment will be administered according
to the most recent guidelines [38]. Timing and schedule of
all the procedures projected during the protocol visits are
detailed in the flow chart table that is available below. See
also Additional file 1 for details related to main pharmaco-
logical interactions and adverse events definition and
reporting.
Compliance
Given that the administration of the drugs is conducted
while the patients are hospitalized, the compliance to the
treatment scheduled must be considered by default as
100% endorsed. Nevertheless, in case any of the requested
doses are not to be administered, the issue and the rele-
vant reason will be documented by the Investigator (and/
or his delegates) on the appropriate source document.
Discontinuation/stopping of the treatment
Enrolled subjects may be discontinued from the investi-
gational product (IP) in case of consent withdrawal, any
adverse event, and non-compliance to study protocol or
incorrect enrollment.
Data collection and management
The referent and person responsible for the coordinating
center, Fondazione Policlinico Universitario Agostino
GemelIi, will be Italo Porto, MD, PhD. The source data, re-
corded in the appropriate source documentation, will be
reported by the Principal Investigator and/or his delegates
in a web-based database (electronic case report form,
eCRF). The validation of the inconsistencies (change or ac-
ceptance) will be made by the Principal Investigator and/
or his delegates. Before the data freezing, the person in
charge of the data management will code the medical
terms. Data will be collected by their registered delegates
and will be stored in dedicated paper file, which will be
locked for security. The electronic data (the eCRF) will be
password secured.
Inspections
The Principal Investigator and/or his delegates must
allow the regulatory authorities to conduct inspections.
The inspection on the part of the Regulatory Authority
consists of an official review of the documents, facilities,
records, and any other resource considered by the au-
thority to relate to the study. Auditing of the trial con-
duct will be performed according to the CTC Quality




Patients satisfying inclusion criteria and having none of
the exclusion criteria will be randomized to either tica-
grelor or clopidogrel (Figs. 1 and 2). Ticagrelor will be
administered in a loading dose of 180 mg followed by a
dose of 90 mg twice daily. Clopidogrel will be adminis-
tered in a loading dose of 600 mg, followed by a dose of
75 mg once a day. If the patient is chronically on ticagre-
lor or clopidogrel treatment, the loading dose will be
omitted.
All patients will receive acetylsalicylic acid (aspirin) at
a dose of 75 to 100mg daily. For those who had not pre-
viously been receiving aspirin, 250 or 325mg will be the
preferred loading dose. The study drug will be continued
for at least 72 h before the second PCI.
During PCI, two sequential balloon inflations will be
performed to measure ischemic preconditioning. Opera-
tors will measure the degree of ST-segment elevation by
intracoronary ECG and by surface ECG during coronary
balloon inflation.
Randomization
Patients will be randomly assigned to ARM A (clopi-
dogrel) or ARM B (ticagrelor) in a 1:1 ratio. The
allocation to the assigned treatment arm will be
known to the patients and to the Principal Investiga-
tor (PI) and/or his delegates.
The randomization will be performed at Visit 0.
Randomization process will be performed printing 50
tags reporting the word “Ticagrelor” and 50 tags report-
ing the word “Clopidogrel” inserted into anonymous
white letter envelopes; the envelopes will be mixed and
then stacked up in random order, with the opening side
toward the bottom of the pile, by the study monitor; the
resulting random sequence of 100 envelopes will be con-
signed to the PI or his delegates, which are entrusted
with their preservation and responsible for any adulter-
ation. At visit 0 the PI or his delegates will open the first
available envelope, proceeding from top to bottom of
the pile. The already opened envelopes will be stored
separately from the others and will be available to the
study monitor on request.
Study timeline
The study timeline is depicted in Table 1. See also the
checklist enclosed in Additional file 2.
Assessments description
Dyspnea evaluation
The sensation of dyspnea will be reported by patients
using the modified Borg scale; the scale is scored from 1
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(no sensation of dyspnea) to 10 (maximum sensation of
dyspnea) [39].
Assessment of platelet reactivity
We will perform platelet VASP (vasodilator-stimulated
phosphoprotein) and VerifyNow test. The VASP test
specifically assesses the inhibition of platelet reactivity
index (PRI) linked to P2Y12 ADP receptor inhibition.
The VASP test is a flow cytometry-based method that
uses a phosphorylation-specific antibody and measures
the PRI, expressed as a percentage and defined as the
difference in VASP fluorescence intensity between
resting (+PGE1, prostaglandin E1) and activated
(+ADP) platelets. VASP phosphorylation analysis can
evaluate the individual response to the clopidogrel
loading dose prior to PCI and predict post-procedural
major adverse cardiac events (MACE). In a study of
Bonello et al., the optimal cut-off value of PRI
assessed by VASP to exclude adverse events was 50%
[40, 41].
VerifyNow P2Y12 test (Accumetrics, Inc., San Diego,
CA) measures the agglutination of fibrinogen-coated
beads by platelets stimulated by an agonist (ADP with
prostaglandin E1) in citrated whole blood. The rele-
vant thresholds are not clearly defined. Each assay re-
cords two results: P2Y12 reaction units (PRU) and
percentage of inhibition. A good correlation has been
established between the VerifyNow P2Y12 test and
several other methods including the VASP assay [42].
Two blood samples for PRI and PRU testing will be
drawn in Vacutainer tubes containing 3.8% trisodium
citrate. The first sample will be collected at baseline fol-
lowing the randomization and then just before the index
procedure. The analysis and the interpretation will be
carried out in the Department of Cardiovascular Medi-
cine of A. Gemelli Polyclinic or in the Grosseto Hospital
according to the site of enrollment. The authors will
store any residual blood sample for future research
purposes.
For evaluation of the adenosine-induced effect of tica-
grelor compared to clopidogrel, left-overs from the
blood sampling will be utilized to measure the adenosine
plasma concentration in the two groups together with
ENT-1 expression and activity.
Ischemic preconditioning
During PCI, two sequential balloon inflations will be
performed to measure preconditioning. Operators will
measure the degree of ST-segment elevation by intracor-
onary ECG and by surface ECG during coronary balloon
inflation.
Specifically, after passage of the guidewire through a tar-
get stenosis and then advancement of the balloon catheter
across the stenosis, the intracoronary unipolar ECG from
myocardium distal to the stenosis to be dilated will be ob-
tained, connecting the proximal end of the guidewire as it
exited from the balloon catheter. The unipolar intracoron-
ary ECG will be filtered between 0.1 to 100 or 0.1 to 500
Hz and then displayed simultaneously with the standard
surface leads being monitored. Surface and intracoronary
ECGs will be recorded simultaneously and continuously
during balloon inflation and deflation [43–45].
Moreover, angina score during coronary balloon infla-
tion will be registered by using a Visual Analog Scale
(VAS) on a scale of 0 (no pain) to 10 (most severe pain)
[46]. For pharmacodynamic considerations, the Index
PCI will be performed at 4 ± 1 h after ticagrelor or clopi-
dogrel last dose.
Quantification of coronary microvascular resistance
CFR and IMR will be measured with an intracoronary
pressure/temperature sensor-tipped guidewire (Radi
pressure wire 4, Radi Medical Systems, Wilmington,
Mass., USA), with an accuracy of 0.05 °C within a
temperature range of 15–42 °C, to derive thermodilu-
tion curves. Previous experimental and human studies
have demonstrated that the mean transit time (Tmn)
of an intracoronary injection of saline at room
temperature, derived from thermodilution curves, is
inversely proportional to coronary flow [47–49].
Therefore, a given percent decrease in Tmn closely
reflects a proportional percent increase in coronary
blood flow. Three injections (3 mL each) of saline at
room temperature will be performed, and the resting
Tmn will be measured. An intravenous infusion of
adenosine (Adenoscan, Sanofi Aventis S.p.A, Milan,
Italy) at 140 μg/kg/min will be administered to induce
a steady-state maximal hyperemia, followed by three
further injections (3 mL) of room temperature saline
to measure hyperemic Tmn.
Simultaneous measurements of mean aortic pressure
(Pa, through the guiding catheter) and mean distal
coronary pressure (Pd, by the pressure wire) will also be
obtained in the resting and maximal hyperemic states.
The following parameters will be calculated:
1. CFR will be calculated as the resting Tmn divided
by the hyperemic Tmn [47, 48]
2. IMR will be calculated as the distal coronary
pressure at maximal hyperemia divided by the
inverse of the hyperemic Tmn [50]
3. BR (Baseline resistance index) will be calculated
using the equation: BR = Pabase ×Tmnbase (Pdbase
–Pw)/(Pabase –Pw) [51]
4. RRR (resistive reserve ratio) will be calculated using
the following equation: RRR = BR index / IMR [49, 50]
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Statistical analysis
All the variables will be descriptively analyzed by arm
and visit (mean, median, standard deviation, minimum
and maximum for continuous variables, and frequency
distribution for categorical variables). Categorical vari-
ables referring to a physical examination, vital signs
and laboratory abnormalities will also be analyzed
with shift tables (baseline vs. final visit). All analyses
will be carried out in details in the respective Statis-
tical Analysis Plan (SAP), which will be finalized in
Version 1.0 before the database freezing.
Version 2.0 of the SAP will be prepared after the
Data Review Meeting (in which the protocol viola-
tions will be evaluated) and will include the list of
the patients belonging to the defined populations and
the randomization list.
A descriptive analysis of demographic data and base-
line characteristics will be carried out to verify the bal-
ance of the two arms at the study entry.
The delta ST-segment elevation by intracoronary ECG
during two-step sequential coronary balloon inflation in
the culprit vessel will be compared between the ticagre-
lor and clopidogrel arms by using two-way ANOVA
(2 × 2). Missing data in the primary analysis will be han-
dled by simple imputations. An interim efficacy analyses
Table 1 A TAPER-S study timeline
Screening and Randomization
V0 – Days -3 to -1
Signed and dated Informed Consent obtained prior to start any
procedure scheduled for the study




Vital Signs (BP, HR)
NYHA Class definition
Pregnancy Test (serum test or urine test as per decision of the
clinician)
Full Blood Count, Chemistry and Coagulation Tests
ECG
Echocardiography, if not performed within the last year from the
Informed Consent signature
Chest X-Ray







V1 – Day 0
Verification and confirmation of the inclusion/exclusion criteria
Vital Signs (BP, HR)
ECG
Ischemic Preconditioning
Quantification of coronary microvascular resistance








V2 – Day 1
Physical Examination
Vital Signs (BP, HR)
ECG








V3 – Day 2
Physical Examination






Discharge/End of Study Visit
V4 – Day 3 to Day 5
Physical Examination
Vital Signs (BP, HR)
ECG
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will be conducted after the accrual of two-third of ther-
andomized patients have been reached.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4116-7.
Additional file 1. Details related to main pharmacological interactions
and adverse events definition and reporting are provided in the
additional file, enclosed in the manuscript.
Additional file 2. SPIRIT 2013 Checklist.
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